BIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug; Pfizer’s gene therapy setback; Foresite’s $900M fund

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Assertio denies activist investor’s claims of fraud in open letter

Assertio Holdings responded to activist investor Alexander Parker after Parker’s firm accused Assertio of fraud. The Buxton Helmsley Group on Friday released an open letter

November 12, 2024

Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch

VABYSMO gained FDA approval in January 2022. Credit: Jo Panuwat D via Shutterstock. Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO,

May 1, 2024

Is your happiness hardwired? New study dives into the genetics of joy

The study reveals that the genetic basis for happiness is consistent across various age groups and ancestral backgrounds, influencing well-being measures like confidence and calmness.

October 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.